A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Dose-Response Relationship of Multiple Doses of GSK2269557 Administered as a Dry Powder to Chronic Obstructive Pulmonary Disease (COPD) Patients

NCT ID: NCT02130635

Last Updated: 2018-10-11

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 64 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-07-31
• Study Completion Date: 2015-08-18

Brief Summary

This is a randomised, double-blind, placebo controlled, parallel group study to evaluate the safety, tolerability, pharmacokinetics and dose response of multiple doses of GSK2269557 administered as a dry powder in COPD subjects. Pharmacodynamic effects on biomarkers will also be assessed. This study will have two parts. In Part A, subjects will be randomized to active or placebo treatment in a 3:1 ratio and in Part B, to placebo or one of the six doses of active treatment in an equal ratio. A sufficient number of COPD subjects (male and female of non-child bearing potential) will be screened to ensure that approximately 30 subjects are enrolled and at least 20 evaluable subjects are obtained for Part A and approximately 35 subjects will be enrolled for Part B. In both the parts, subjects will receive study treatment once daily for 14 consecutive days. Placebo control will be included for a valid evaluation of adverse events attributable to treatment versus those independent of treatment.

Conditions

Pulmonary Disease, Chronic Obstructive

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Part A: GSK2269557 1000 MCG

Subjects will receive 2 inhalations (2 x GSK2269557 500 mcg = total dose of 1000 mcg GSK2269557) 30 seconds apart, once daily for 14 consecutive days

Group Type: EXPERIMENTAL

GSK2269557 500 MCG

Intervention Type: DRUG

500 mcg of GSK2269557 blended with lactose per blister administered using a dry powder inhaler device

Part A: PLACEBO

Subjects will receive 2 inhalations of placebo once daily for 14 consecutive days

Group Type: PLACEBO_COMPARATOR

PLACEBO

Intervention Type: DRUG

Lactose administered using a matching dry powder inhaler device

Part B: GSK2269557 100 MCG

Subjects will receive 4 inhalations (1 x GSK2269557 100 mcg and 3 x Placebo = total dose of 100 mcg GSK2269557) 30 seconds apart, once daily for 14 consecutive days

Group Type: EXPERIMENTAL

GSK2269557 100 MCG

Intervention Type: DRUG

100 mcg of GSK2269557 blended with lactose per blister administered using a dry powder inhaler device

PLACEBO

Intervention Type: DRUG

Lactose administered using a matching dry powder inhaler device

Part B: GSK2269557 200 MCG

Subjects will receive 4 inhalations (2 x GSK2269557 100 mcg and 2 x Placebo = total dose of 200 mcg GSK2269557) 30 seconds apart, once daily for 14 consecutive days

Group Type: EXPERIMENTAL

GSK2269557 100 MCG

Intervention Type: DRUG

100 mcg of GSK2269557 blended with lactose per blister administered using a dry powder inhaler device

PLACEBO

Intervention Type: DRUG

Lactose administered using a matching dry powder inhaler device

Part B: GSK2269557 500 MCG

Subjects will receive 4 inhalations (1 x GSK2269557 500 mcg and 3 x Placebo = total dose of 500 mcg GSK2269557) 30 seconds apart, once daily for 14 consecutive days, once daily for 14 consecutive days

Group Type: EXPERIMENTAL

GSK2269557 500 MCG

Intervention Type: DRUG

500 mcg of GSK2269557 blended with lactose per blister administered using a dry powder inhaler device

PLACEBO

Intervention Type: DRUG

Lactose administered using a matching dry powder inhaler device

Part B: GSK2269557 700 MCG

Subjects will receive 4 inhalations (1 x GSK2269557 500 mcg, 2 x GSK2269557 100 mcg and 1 x Placebo = total dose of 700 mcg GSK2269557) 30 seconds apart, once daily for 14 consecutive days

Group Type: EXPERIMENTAL

GSK2269557 100 MCG

Intervention Type: DRUG

100 mcg of GSK2269557 blended with lactose per blister administered using a dry powder inhaler device

GSK2269557 500 MCG

Intervention Type: DRUG

500 mcg of GSK2269557 blended with lactose per blister administered using a dry powder inhaler device

PLACEBO

Intervention Type: DRUG

Lactose administered using a matching dry powder inhaler device

Part B: GSK2269557 1000 MCG

Subjects will receive 4 inhalations (2 x GSK2269557 100 mcg and 2 x Placebo = total dose of 1000 mcg GSK2269557) 30 seconds apart, once daily for 14 consecutive days

Group Type: EXPERIMENTAL

GSK2269557 500 MCG

Intervention Type: DRUG

500 mcg of GSK2269557 blended with lactose per blister administered using a dry powder inhaler device

PLACEBO

Intervention Type: DRUG

Lactose administered using a matching dry powder inhaler device

Part B: GSK2269557 2000 MCG

Subjects will receive 4 inhalations (2 x GSK2269557 100 mcg and 2 x Placebo = total dose of 2000 mcg GSK2269557) 30 seconds apart, once daily for 14 consecutive days

Group Type: EXPERIMENTAL

GSK2269557 500 MCG

Intervention Type: DRUG

500 mcg of GSK2269557 blended with lactose per blister administered using a dry powder inhaler device

Part B: PLACEBO

Subjects will receive 4 inhalations of placebo once daily for 14 consecutive days

Group Type: PLACEBO_COMPARATOR

PLACEBO

Intervention Type: DRUG

Lactose administered using a matching dry powder inhaler device

Interventions

GSK2269557 100 MCG

100 mcg of GSK2269557 blended with lactose per blister administered using a dry powder inhaler device

Intervention Type: DRUG

GSK2269557 500 MCG

500 mcg of GSK2269557 blended with lactose per blister administered using a dry powder inhaler device

Intervention Type: DRUG

PLACEBO

Lactose administered using a matching dry powder inhaler device

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• The subject has a confirmed and established diagnosis of COPD, as defined by the Global Initiative for Chronic Obstructive lung Disease (GOLD) guidelines.
• Male or female of non-child bearing potential between 40 and 75 years of age inclusive, at the time of signing the informed consent.
• The subject has a post-bronchodilator [400 microgram (mcg) salbutamol] Maximal amount of air FEV1/FVC <0.7 and FEV1 >=40% to <=80% of predicted (Predictions should be according to the European Community of Coal and Steel (ECCS) equations).
• Subject is a smoker or an ex-smoker with a smoking history of at least 10 pack years (pack years = (cigarettes per day smoked/20) x number of years smoked)).
• The subject is able to produce >100 milligram (mg) of sputum at screening.
• Body weight >=45 kilogram (kg) and body mass index (BMI) within the range 17 - 32 kg/square meter (m^2) (inclusive).
• A female subject is eligible to participate if she is of: Non-childbearing potential defined as pre-menopausal females with a documented tubal ligation, hysterectomy, salpingo-oophrectomy or oophrectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea [in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) > 40 milli-International units (MIU)/millilitre (mL) and estradiol < 40 picogram (pg)/mL (<147 picomole(pmol)/Liter [L]) is confirmatory]. [Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the contraception methods, if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrolment. For most forms of HRT, at least 2-4 weeks will elapse between the cessation of therapy and the blood draw; this interval depends on the type and dosage of HRT. Following confirmation of their post-menopausal status, they can resume use of HRT during the study without use of a contraceptive method.]; or has only same-sex partners, when this is her preferred and usual lifestyle.
• Male subjects with female partners of child-bearing potential must agree to use one of the contraception methods. This criterion must be followed from the time of the first dose of study medication until the follow-up visit.
• Based on averaged QTcF values of triplicate ECGs obtained over a brief recording period (e.g. 5 minutes): QTcF <450 millisecond (msec); or QTcF<480 msec in subjects with right bundle branch block.
• Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.

Exclusion Criteria

• Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome, asymptomatic gallstones and cholecystectomy).
• Subjects who have a past or current medical condition or diseases that are not well controlled and, which as judged by the Investigator, may affect subject safety or influence the outcome of the study. (Note: Patients with adequately treated and well controlled concurrent medical conditions (e.g. hypertension) are permitted to be entered into the study).
• Subject has a diagnosis of active tuberculosis, lung cancer, clinically overt bronchiectasis, pulmonary fibrosis, asthma or any other respiratory condition that might, in the opinion of the Investigator, compromise the safety of the subject or affect the interpretation of the results.
• History of regular alcohol consumption within 6 months of the study defined as an average weekly intake of >28 units for males or >21 units for females. One unit is equivalent to 8 gram of alcohol: a half-pint (approximately 240 mL) of beer, 1 glass (125 mL) of wine or 1 (25 mL) measure of spirits.
• History of sensitivity to any of the study medications, or components (such as lactose) thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation.
• A positive test for Human immunodeficiency virus (HIV) antibody - tested according to local policies.
• The subject has a positive pre-study drug/alcohol screen. A minimum list of drugs that will be screened for include cannabinoids, amphetamines, barbiturates, cocaine and opiates. The detection of drugs (e.g. benzodiazepines, opiates) taken for a legitimate medical purpose would not necessarily be an exclusion to study participation. The detection of alcohol would not be an exclusion at screening but would need to be negative pre-dose and during the study.
• A positive pre-study Hepatitis B surface antigen (HBs-Ag) or positive total hepatitis B core antibody (anti-HBc IgM) or positive Hepatitis C antibody result within 3 months of screening.
• Pregnant females as determined by positive urine human chorionic gonadotropin (hCG) test at screening or prior to dosing.
• Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.
• Lactating females.
• The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
• Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
• Subject has poorly controlled or unstable COPD, defined as the occurrence of any of the following: Either: acute worsening of COPD (an exacerbation) that is managed by the subject at home requiring treatment with corticosteroids and/or antibiotics in the 4 weeks prior to the screening visit; or more than two exacerbations in the previous 2 months prior to the screening visit that required a course of oral corticosteroids and/or antibiotics, or for which the subject was hospitalised.
• Subject has had a respiratory tract infection treated with antibiotics in the 4 weeks prior to first dose.
• Subject requires regular treatment with oral corticosteroids or has received oral or parenteral corticosteroids within 4 weeks of screening.
• Vulnerable subject (e.g., person kept in detention).
• The subject is not able to understand and communicate in German or native language.

• Minimum Eligible Age: 40 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

GlaxoSmithKline

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

GSK Clinical Trials

Role: STUDY_DIRECTOR

GlaxoSmithKline

Locations

GSK Investigational Site

Großhansdorf, Schleswig-Holstein, Germany

GSK Investigational Site

Berlin, , Germany

Countries

Germany

Related Links

https://clinicalstudydatarequest.com

IPD for this study will be made available via the Clinical Study Data Request site.

Other Identifiers

115119

Identifier Type: -

Identifier Source: org_study_id